Davis Polk advised the representatives of the several underwriters in connection with the $219.9 million initial public offering of 12,937,500 American depositary shares, each representing one ordinary share, of Connect Biopharma Holdings Limited, including the full exercise of the underwriters’ option to purchase 1,687,500 ADSs. The ADSs are listed on the Nasdaq Global Market under the symbol “CNTB.”
Connect Biopharma is a global clinical-stage biopharmaceutical company developing therapies for the treatment of T cell-driven inflammatory diseases. The company’s core expertise is in the use of functional cellular assays with T cells to screen and discover potent product candidates against immune targets.
The Davis Polk corporate team included partners Alan F. Denenberg, James C. Lin and Emily Roberts and associates Dongbiao Shen and Dana Lueck-Mammen. Partner David R. Bauer and associates Jay Frankel and Shuang Ci provided advice on intellectual property matters. Associate Justin Alexander Kasprisin provided executive compensation advice. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California, Hong Kong and New York offices.